YKL-40 is a potential serum biomarker of distinct benign and malignant disease states, including diabetes mellitus, coronary artery disease, systemic sclerosis, psoriasis, dementia, benign prostatic hyperplasia, cervical cancer, and primary prostate cancer [14–17, 28, 29]. Here, CHI3L1 is linked to systemic sclerosis.